Attitudes and acceptance of oral and parenteral HIV preexposure prophylaxis among potential user groups: A multinational study

PLoS ONE

Volumn 7, Issue 1, 2012, Pages

  Eisingerich, Andreas B ^a   Wheelock, Ana ^b   Gomez, Gabriela B ^c   Garnett, Geoffrey P ^b   Dybul, Mark R ^d   Piot, Peter K ^e  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c AMSTERDAM INSTITUTE FOR GLOBAL HEALTH AND DEVELOPMENT   (Netherlands)

^d GEORGETOWN UNIVERSITY LAW CENTER   (United States)

^e LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADOLESCENT; ADULT; ADVERSE OUTCOME; AGE DISTRIBUTION; ANALYSIS OF VARIANCE; ARTICLE; CONDOM; CONTROLLED STUDY; FEMALE; GEOGRAPHIC DISTRIBUTION; GROUP DYNAMICS; HEALTH PROGRAM; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INFECTION RISK; INFORMATION DISSEMINATION; MAJOR CLINICAL STUDY; MALE; PATIENT ATTITUDE; PATIENT PREFERENCE; POPULATION RESEARCH; PREEXPOSURE PROPHYLAXIS; PREMEDICATION; SEXUAL BEHAVIOR; ATTITUDE TO HEALTH; CLINICAL TRIAL; HUMAN IMMUNODEFICIENCY VIRUS; INTERNATIONAL COOPERATION; MULTICENTER STUDY; PATHOGENICITY; SOUTH AFRICA; STATISTICS; VIROLOGY;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; ATTITUDE TO HEALTH; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HIV; HIV INFECTIONS; HIV SEROPOSITIVITY; HUMANS; INTERNATIONAL AGENCIES; MALE; PATIENT ACCEPTANCE OF HEALTH CARE; SOUTH AFRICA; YOUNG ADULT;

EID: 84855656304     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0028238     Document Type: Article

References (43)

1. UNAIDS (2010) Report on the global AIDS epidemic Geneva.
2. NIAID (2011) Treating HIV-infected People with Antiretrovirals Protects Partners from Infection. Available: http://www.niaid.nih.gov/news/newsreleases/2011/Pages/HPTN052.aspx. Accessed 2011 Jun 19.
3. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, et al. (2010) Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in Women. Science 329: 1168-1174.
4. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, et al. (2010) Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men. New Engl J Med 363: 2587-2599.
5. Roehr B, (2011) Tenofovir works as pre-exposure prophylaxis against HIV, two studies confirm. BMJ 343: d4540.
6. Roehr B, (2011) HIV prevention trial in women is abandoned after drugs show no impact on infection rates. BMJ 342: d2613.
7. MTN (2011) Microbicide Trials Network Statement on Decision to Discontinue Use of Oral Tenofovir Tablets in VOICE, a Major HIV Prevention Study in Women. Press release: The Microbicide Trials Network. National Institute of Allergy and Infectious Diseases.
8. CDC (2011) Interim Guidance: Preexposure Prophylaxis for the Prevention of HIV Infection in Men Who Have Sex with Men. 60: 65-68.
9. Bertozzi SM, Laga M, Bautista-Arredondo S, Coutinho A, (2008) Making HIV prevention programmes work. Lancet 372: 831-844.
10. Frost LJ, Reich MR, (2009) Creating Access To Health Technologies In Poor Countries. Health Affair 28: 962-973.
11. McGowan I, Gomez K, Bruder K, Febo I, Chen BA, et al. (2011) Phase 1 randomized trial of the vaginal safety and acceptability of SPL7013 gel (VivaGel) in sexually active young women (MTN-004). AIDS 25: 1057-1064.
12. Kamali A, Byomire H, Muwonge C, Bakobaki J, Rutterford C, et al. (2010) A randomised placebo-controlled safety and acceptability trial of PRO 2000 vaginal microbicide gel in sexually active women in Uganda. Sex Transm Infect 86: 222-226.
13. Elias C, Coggins C, (2001) Acceptability Research on Female-Controlled Barrier Methods to Prevent Heterosexual Transmission of HIV: Where Have We Been? Where Are We Going? J Womens Health Gend Based Med 10: 163-173.
14. Liu AY, Kittredge PV, Vittinghoff E, Raymond HF, Ahrens K, et al. (2009) Limited knowledge and use of HIV post- and pre-exposure prophylaxis among gay and bisexual men. J Acq Immun Def Synd 47: 242-247.
15. Nodin N, Carballo-Diéguez A, Ventuneac AM, Balan IC, Remien R, (2008) Knowledge and acceptability of alternative HIV prevention bio-medical products among MSM who bareback. AIDS Care 20: 106-115.
16. Voetsch AC, Heffelfinger JD, Begley EB, Jafa-Bhushan K, Sullivan PS, (2007) Knowledge and Use of Preexposure and Postexposure Prophylaxis Among Attendees of Minority Gay Pride Events, 2005 Through 2006. JAIDS 46: 378-380.
17. Kellerman SE, Hutchinson AB, Begley EB, Boyett BC, Clark HA, et al. (2006) Knowledge and Use of HIV Pre-Exposure Prophylaxis Among Attendees of Minority Gay Pride Events, 2004. JAIDS 43: 376-377.
18. Guest G, Shattuck D, Johnson L, Akumatey B, Clarke Kekawo EE, et al. (2010) Acceptability of PrEP for HIV Prevention Among Women at High Risk for HIV. J Womens Health 19: 791-798.
19. Galea JT, Kinsler JJ, Salazar X, Lee S-J, Giron M, et al. (2011) Acceptability of pre-exposure prophylaxis as an HIV prevention strategy: barriers and facilitators to pre-exposure prophylaxis uptake among at-risk Peruvian populations. Int J STD AIDS 22: 256-262.
20. UNAIDS (2008) Report on the global AIDS epidemic. Geneva.
21. Sudman S, Blair E, (1999) Sampling in the Twenty-First Century. J Acad Market Sci 27: 269-277.
22. Cooper DR, Schindler PS, (2001) Business Research Methods New York McGraw-Hill/Irwin.
23. Schroder K, Carey M, Vanable P, (2003) Methodological challenges in research on sexual risk behavior: II. Accuracy of self-reports. Ann Behav Med 26: 104-123.
24. Krosnick JA, Berent MK, (1993) Comparisons of Party Identification and Policy Preferences: The Impact of Survey Question Format. Am J Polit Sci 37: 941-964.
25. Krosnick JA, (1991) Response strategies for coping with the cognitive demands of attitude measures in surveys. Appl Cognitive Psych 5: 213-236.
26. Paxton L, Hope T, Jaffe H, (2007) Pre-exposure prophylaxis for HIV infection: what if it works? Lancet 370: 89-93.
27. Kelesidis T, Landovitz R, (2011) Preexposure Prophylaxis for HIV Prevention. Curr HIV/AIDS Rep 8: 94-103.
28. Ickovics JR, Meisler AW, (1997) Adherence in AIDS clinical trials: A framework for clinical research and clinical care. J Clin Epidemiol 50: 385-391.
29. Bridges JFP, (2003) Stated preference methods in health care evaluation: an emerging methodological paradigm in health economics. Appl Health Econ Health Policy 2: 213-224.
30. Ryan M, Scott DA, Reeves C, Bate A, van Teijlingen ER, et al. (2001) Eliciting public preferences for healthcare: a systematic review of techniques. Health Technol Assess 5.
31. Geronimus AT, Bound J, Neidert LJ, (1996) On the Validity of Using Census Geocode Characteristics to Proxy Individual Socioeconomic Characteristics. J Am Stat Assoc 91: 529-537.
32. Hanck SE, Blankenship KM, Irwin KS, West BS, Kershaw T, (2008) Assessment of Self-Reported Sexual Behavior and Condom Use Among Female Sex Workers in India Using a Polling Box Approach: A Preliminary Report. Sex Transm Dis 35: 489-494.
33. Gregson S, Zhuwatu T, Ndlovu J, Nyamukapa CA, (2002) Methods to Reduce Social Desirability Bias in Sex Surveys in Low-Development Settings: Experience in Zimbabwe. Sex Transm Dis 29: 568-575.
34. Maman S, Abler L, Parker L, Lane T, Chirowodza A, et al. (2009) A comparison of HIV stigma and discrimination in five international sites: The influence of care and treatment resources in high prevalence settings. Soc Sci Med 68: 2271-2278.
35. Beyrer C, Baral S, Kerrigan D, El-Bassel N, Bekker L-G, et al. (2011) Expanding the Space: Inclusion of Most-at-Risk Populations in HIV Prevention, Treatment, and Care Services. JAIDS 57: 96-99.
36. Parker RG, Easton D, Klein CH, (2000) Structural barriers and facilitators in HIV prevention: a review of international research. AIDS 14: 22-32.
37. Schneider H, Blaauw D, Gilson L, Chabikuli N, Goudge J, (2006) Health Systems and Access to Antiretroviral Drugs for HIV in Southern Africa: Service Delivery and Human Resources Challenges. Reprod Health Matter 14: 12-23.
38. Myers GM, Mayer KH, (2011) Oral Preexposure Anti-HIV Prophylaxis for High-Risk U.S. Populations: Current Considerations in Light of New Findings. AIDS Patient Care ST 25: 63-71.
39. Underhill K, Operario D, Mimiaga M, Skeer M, Mayer K, (2010) Implementation Science of Pre-exposure Prophylaxis: Preparing for Public Use. Curr HIV/AIDS Rep 7: 210-219.
40. Coates TJ, Richter L, Caceres C, (2008) Behavioural strategies to reduce HIV transmission: how to make them work better. Lancet 372: 669-684.
41. Padian NS, Buvé A, Balkus J, Serwadda D, Cates W, (2008) Biomedical interventions to prevent HIV infection: evidence, challenges, and way forward. Lancet 372: 585-599.
42. Abbas UL, Anderson RM, Mellors JW, (2007) Potential Impact of Antiretroviral Chemoprophylaxis on HIV-1 Transmission in Resource-Limited Settings. PLoS ONE 2: e875.
43. Espey E, Ogburn T, (2011) Long-Acting Reversible Contraceptives: Intrauterine Devices and the Contraceptive Implant. Obstet Gynecol 117: 705-719.